Molecular Templates is in the final stage of its post-confirmation wind-down, with the liquidating trustee asking the court to close the Chapter 11 cases after asserting that the estates are fully administered, the plan has been substantially consummated, all assets have been liquidated and all contested matters and adversary proceedings have been resolved. A final distribution to allowed general unsecured creditors remains pending receipt of required tax forms, and the trustee’s final-decree motionDkt. 267 is set for August 19, 2026, with objections due August 7.

The clinical-stage biotechnology company entered Chapter 11 on April 20, 2025, after a prolonged capital and strategic-alternatives process failed to produce sufficient financing or a buyer. The termination of its Bristol Myers Squibb collaboration in June 2024 compounded an already severe liquidity shortfall; Molecular Templates ceased operations and terminated all employees at year-end 2024, then sold laboratory equipment in March 2025 for approximately $1.2 million, applying the proceeds to secured debt. At filing, it reported approximately $29.4 million of obligations, including about $25.7 million owed to K2 HealthVentures under a secured contingent-value-right agreement and bridge loan, as described in the first-day declarationDkt. 15.

With only approximately $2,000 of cash at the outset, the debtors pursued a lender-supported plan rather than a going-concern sale. K2 proposed a $12 million superpriority DIP facility comprising $3 million of new money and a $9 million roll-up, subject to an accelerated plan timetable, under the DIP financing motionDkt. 14. The combined disclosure statement and planDkt. 25 contemplated issuing all reorganized equity to K2 in satisfaction of secured claims, cancelling existing equity, and transferring retained assets and avoidance actions to a liquidating trust for general unsecured creditors. The plan became effective on July 18, 2025, and the trust reported no claim distributions through June 30, 2026, notwithstanding approximately $969,000 of cumulative cash disbursements since effectiveness, in its latest post-confirmation reportDkt. 269. As a protective measure while closure is pending, the trustee also seeks to extend the claims-objection deadline to October 19, 2026; that extension motionDkt. 266 carries a July 31 objection deadline and is scheduled for the same August 19 hearing.